EQRx Raises White Flag On Its Low-Cost Drug Business Model
The company is backing out of the development of several clinical-stage assets and will cut 170 positions while it changes its business strategy.
The company is backing out of the development of several clinical-stage assets and will cut 170 positions while it changes its business strategy.